Puma Biotechnology, Inc.

NASDAQ:PBYI

Biotechnology

Healthcare
$7.22 +2.21%

+$0.16 today

Market cap
$373.26M
Beta
1.21
P/E (TTM)
15.4
EPS (TTM)
$0.48
52W Low $3.03High $7.90

Volume 0.45M

Average 0.26M

PBYI Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Puma Biotechnology, Inc.NASDAQ: PBYI

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses turns positive

Q1 FY2026 other income / expenses was $401K, compared with -$717K a year earlier. Trailing-twelve-month other income / expenses was -$399K.

Context

  • Other income / expenses amounted to 0.7% of revenue in FY2025, down 2.3 pp from a year earlier.
  • Other income / expenses grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other income / expenses holds near $401K or moves back toward the trailing-twelve-month quarterly average of -$99.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$401K+40000.0% QoQ
Last fiscal yearDec 2025
-$1.52M+77.9% YoY
LTMMar 2026
-$399K+92.5% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+155.9%——
1 year+77.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(1.52M) USD
Year-over-year change
+77.9%

Other Income / Expenses vs competitors

How PBYI compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +92.5% is the 3rd highest of 11, against a peer median of -14.0%.
  • Other income / expenses amounts to 0.2% of revenue for PBYI, versus a peer median of 26.9%.
PBYI Competitors
Other Income / Expenses for PBYI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NBPNovaBridge BiosciencesLTM Sep 2025CN¥21.66M CNY+125.8%——
TNGXTango Therapeutics, Inc.LTM Sep 2026$20.48M USD+106.3%+48.7%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$14.69M USD+6.7%+72.3%—
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$11.63M USD-10.2%——
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$10.06M USD+10.6%+14.6%—
CRDFCardiff Oncology, Inc.LTM Mar 2026$2.67M USD-17.9%+37.4%507.8%
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$127.98K CAD-93.2%-66.7%—
PBYIPuma Biotechnology, Inc.LTM Mar 2026-$399K USD+92.5%—0.2%
MGNXMacroGenics, Inc.LTM Mar 2026-$7.37M USD-116.5%—4.7%
NUVBNuvation Bio Inc.LTM Jun 2026-$12.2M USD-156.1%-18.4%7.2%
VSTMVerastem, Inc.LTM Mar 2026-$23.11M USD-31.1%—46.6%
Peer median (excluding PBYI) —-14.0%+26.0%26.9%

Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue253.16M228.03M235.64M230.47M228.37M
Cost of Revenue63.7M55.09M62.68M64.4M58.16M
Gross Profit189.45M172.94M172.96M166.06M170.21M
Gross Margin74.8%75.8%73.4%72.1%74.5%
Research & Development71.87M52.24M50.38M54.94M62.07M
Selling, General & Admin116.29M89.98M89.31M80.16M71.21M
Operating Expenses188.16M149.22M140.32M135.1M132.92M
Depreciation & Amortization11.31M9.84M11.52M11.52M10.94M
EBITDA(4.69M)21.89M47.52M48.08M53.34M
EBITDA Margin-1.9%9.6%20.2%20.9%23.4%
Operating Income1.29M23.72M32.64M30.97M37.3M
Operating Margin0.5%10.4%13.9%13.4%16.3%
Interest Income160K813K2.61M4.72M4.08M
Interest Expense12.81M11.59M13.33M12.45M6.62M
Other Income / Expenses(30.09M)(23.26M)(9.97M)(6.87M)(1.52M)
Income Before Tax(28.8M)457K22.67M24.1M35.78M
Pre-Tax Margin-11.4%0.2%9.6%10.5%15.7%
Income Tax Expense324K455K1.08M(6.18M)4.67M
Net Income(29.13M)2K21.59M30.28M31.11M
Net Margin-11.5%0.0%9.2%13.1%13.6%
EPS (Basic)(0.72)0.020.460.620.62
EPS (Diluted)(0.72)0.020.450.620.61
Weighted Avg Shares40.64M44.67M47.13M48.65M50.01M
Weighted Avg Shares (Diluted)40.64M44.93M47.55M49.1M50.65M

Puma Biotechnology, Inc.

NASDAQ:PBYI

Intrinsic Alpha fair value

Locked

Current Price

$7.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.